These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31366860)

  • 41. [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
    Carlavilla AB; López-Medrano F; Chaves F; Villena V; Echave-Sustaeta J; Aguado JM
    Enferm Infecc Microbiol Clin; 2005 May; 23(5):270-3. PubMed ID: 15899177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
    Domínguez-Herrera J; Velasco C; Docobo-Pérez F; Rodríguez-Martínez JM; López-Rojas R; Briales A; Pichardo C; Díaz-de-Alba P; Rodríguez-Baño J; Pascual A; Pachón J
    J Antimicrob Chemother; 2013 Jul; 68(7):1609-15. PubMed ID: 23493313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
    Takahashi M; Takahashi K; Ogawa K; Takashima T; Asano Y; Kashiwagi S; Noda S; Onoda N; Ohira M; Nagayama K
    Support Care Cancer; 2019 Aug; 27(8):2829-2836. PubMed ID: 30547304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and in vivo antibacterial activity of modithromycin against streptococci and Haemophilus influenzae.
    Sato T; Kawai Y; Matsuda H; Tateda K; Kimura S; Ishii Y; Yamaguchi K; Gotoh N
    J Antimicrob Chemother; 2011 Jul; 66(7):1547-54. PubMed ID: 21511823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.
    Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva.
    Suzuki T; Yamamoto T; Ohashi Y
    J Infect Chemother; 2016 Jun; 22(6):360-5. PubMed ID: 27036073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision.
    Fratoni AJ; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2021 Dec; 77(1):164-168. PubMed ID: 34542637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
    Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
    Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
    Kashimoto Y; Kurosaka Y; Karibe Y; Uoyama S; Fujikawa K; Namba K; Otani T; Yamaguchi K
    Jpn J Antibiot; 2009 Oct; 62(5):452-9. PubMed ID: 20055122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.
    Homma T; Kawahara T; Mikuni H; Uno T; Sato H; Fujiwara A; Uchida Y; Fukuda Y; Manabe R; Ida H; Kuwahara N; Kimura T; Hirai K; Miyata Y; Jinno M; Yamaguchi M; Kishino Y; Murata Y; Ohta S; Yamamoto M; Watanabe Y; Yamaguchi H; Kusumoto S; Suzuki S; Tanaka A; Yokoe T; Ohnishi T; Sagara H
    Int Arch Allergy Immunol; 2019; 178(4):355-362. PubMed ID: 30759444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
    Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
    Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis.
    Peterson J; Yektashenas B; Fisher AC
    Curr Med Res Opin; 2009 Mar; 25(3):559-68. PubMed ID: 19196225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae.
    Anderegg TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):213-7. PubMed ID: 15541608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.